Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026  Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) — Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the fourth quarter and full year ended December 31, 2025.   “We made significant strides advancing our pipeline in the past year, and 2026 has already delivered a meaningful milestone with positive Phase...

Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted  Company to host conference call and webcast TODAY, March 9, 2026, at 4:30 p.m. ET BOSTON, March 09, 2026 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended December 31, 2025. “MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, and its strong, accelerating performance reinforces our confidence in its long-term potential,” said Neil F. McFarlane, Zevra’s President...

SHAKOPEE, Minn., March 09, 2026 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC) today reported financial results for the fourth quarter and full year ended December 31, 2025.($ in thousands, except per share data and percentages)         Three Months Ended December 31,   Twelve Months Ended December 31,  2025   2024   Change   2025   2024   ChangeNet revenues  $12,446   $11,978   3.9%   $59,568   $61,562   (3.2%)                       Net income (loss) (1) ($390)   ($1,245)   (68.7%)   ($529)   $2,113   (125.1%)                       Adjusted EBITDA (2) $2,288   $1,497   52.8%   $9,410   $10,805   (12.9%)                       Basic EPS ($0.08)   ($0.25)   (68.0%)   ($0.10)   $0.42   (123.8%)Diluted EPS ($0.08)   ($0.25)   (68.0%)   ($0.10)   $0.42   (123.8%) (1)   Net...

HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) — Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today updates to its strategic initiatives, year-end 2025 proved reserves, operating and financial results for the fourth quarter and full-year 2025, and full-year 2026 development plans and guidance for the Company. Strategic Initiatives Update In the third quarter of 2025, Amplify communicated its strategic plan with three core tenets: (1) simplify the portfolio, (2) strengthen the balance sheet, and (3) focus resources on our assets with the highest potential upside opportunities. In 2025, the Company made significant progress on all three fronts. Key highlights include:Completed six separate transactions for total consideration of approximately $250 million (excluding certain post-closing adjustments)In...

Net Asset Value of $8.09 Per Share as of December 31, 2025 Recent 2026 Portfolio Company Financings Expected to Add an Estimated $5.00 – $6.50 to Net Asset Value Per Share NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) — SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. Net assets totaled approximately $205.3 million, or $8.09 per share, at December 31, 2025, as compared to $9.23 per share, at September 30, 2025 and $6.68 per share at December 31, 2024. “2025 was a year of strong performance across our portfolio, underscoring the continued execution and value creation at several of our largest investments. That momentum has continued into 2026, with a number of our portfolio companies having...

Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million. Successfully launched oral Wegovy subsequent to year end, with over 80% of new weight management patients initiating branded therapy and Q1 sign-ups at record levels. Exited 2025 with $36.8 million of cash and no debt, positioning LifeMD for accelerated investments in growth. Benefits infrastructure on track to cover approximately 220 million Americans in second quarter; women’s health offering seeing strong early patient growth.Conference call begins at 4:30 p.m. Eastern time today NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results...

– Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment – – Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial – – $76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation – JERUSALEM, March 09, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the...

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. “The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I’m proud of what our team has accomplished and excited for the year ahead,” said David Fischel, Chairman and CEO. “The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, and MAGiC Sweep high density mapping catheter. This core product portfolio serves as a foundation for significant commercial growth as the only...

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030, a first-in-class TOP1i-based ADC, on track for 3Q 2026 Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product pipeline. “I am excited about MacroGenics’...

– Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 –  – Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 – – Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile – – Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 – LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2025 financial and operating results. “Building on our pipeline progress in 2025, Voyager expects 2026 to be a pivotal year...